ClinicalTrials.gg
RecruitingNCT05407610COGENIUSUpdated May 24, 2023

Comparison of Conventional and Cooled Radiofrequency of the Genicular Nerves in Patients With Chronic Knee Pain

An interventional study of Conventional Radiofrequency ablation of the genicular nerves and Cooled Radiofrequency ablation of the genicular nerves in Knee Osteoarthritis, Persistent Postsurgical Pain and Chronic Knee Pain, sponsored by Ziekenhuis Oost-Limburg. Recruiting at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-24.

Sponsored by Ziekenhuis Oost-Limburg · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Osteoarthritis, Knee with a site in Belgium — 6 open to participants now, 11 under way, none of them phase 3. Osteoarthritis, Knee · Belgium.

Planned enrollment
5th of 38
400 · median 86
Started
2022
with 3 others
No phase
25 of 46
6 open now
Primary completion
2025-03
later than 4 of 10 live
Registered
38th of 46
by date
Lead sponsor
2 of 46
Ziekenhuis Oost-Limburg

Among the 46 studies in Osteoarthritis, Knee with a site in Belgium, this one is the 5th largest by planned enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2022, is one of 25 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 38th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

6 of the 46 studies in Osteoarthritis, Knee with a site in Belgium are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Osteoarthritis, Knee with a site in Belgium, or all of them as a file.
02

Study summary

Chronic knee pain remains a disabling disease despite current treatment strategies. There is an increase in the prevalence of osteoarthritis (OA) of the knee in the general population, presently affecting approximately 450,000 individuals in Belgium. A total knee replacement is a viable alternative for severe knee OA that does not respond to conservative therapy. Unfortunately, up to 53% of patients who undergo a total knee replacement develop persistent post-surgical pain (PPSP). There is currently no effective therapy for PPSP.

A radiofrequency (RF) treatment applies high frequency current on the nerve responsible for pain conduction, resulting in an interruption of the transmission of pain. This can be applied to the nerves innervating the knee joint - the superolateral, superomedial and inferomedial genicular nerves - and could be an alternative, minimally invasive treatment for patients with knee OA who fail conservative treatments and for patients with PPSP. Data from the recent literature indicates that this treatment leads to a reduction of pain intensity and could result in an improvement of knee function, of the psychological state of the individual, and finally in an increase in health-related quality of life. Furthermore, RF of the genicular nerves could help avoid or delay a total knee replacement therefore potentially contributing to cost reduction. Both cooled and conventional RF treatments are reported in the literature to improve pain. The use of water to cool the RF electrodes results in an increased lesion size by removing heat from adjacent tissue, allowing power delivery to be increased. As a consequence, cooled RF could result in a higher chance of success and longer duration of effect. Until now, the studies performed on cooled RF are industry initiated and a direct comparison between conventional, cooled and a sham procedure is lacking.

The aim of the COGENIUS trial is to investigate the effect of the two types of RF treatment on individuals experiencing chronic knee pain that is resistant to conservative treatments. For this purpose, the efficacy and cost-effectiveness of cooled and conventional RF will be compared to a sham procedure in patients suffering from knee OA and PPSP after total knee replacement.

Read the detailed description

In this three-arm, pragmatic, prospective, multicentre, double blind, randomised sham-controlled trial of approximately 4 years duration, 400 patients with chronic moderate to severe anterior knee pain (>12 months) refractory to conventional treatments will be included. Two groups of chronic knee pain patients will be enrolled depending on the aetiology of knee pain: OA and PPSP. Each patient will undergo a run-in period of 1 to 3 months depending on the previous treatments of the patient. A run-in period is added to the trial to guarantee that conservative treatment is performed in an optimal way before randomisation. In each group (osteoarthritis and persistent post-surgical pain), non-responders to the run-in period will be randomly allocated to a conventional RF intervention of the genicular nerves, a cooled RF intervention of the genicular nerves or a sham procedure in a 2:2:1 ratio. The patients will be followed up for a period of 2 years.

03

Conditions studied

  • Knee Osteoarthritis
  • Persistent Postsurgical Pain
  • Chronic Knee Pain

Keywords

  • Osteoarthritis
  • Persistent Postsurgical Pain
  • Knee
  • Radiofrequency ablation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written must be obtained before any study assessment is performed.
  • Adult patients (Age ≥ 18 years old).
  • Chronic anterior knee pain (> 12 months) that is moderate to severe (defined as NRS > 4 on most or all days for the index knee either constantly or with motion at time of screening and, an average NRS score reported in the patient diary >4 at the end of the run-in period).
  • Unresponsive (meaning insufficient pain reduction or intolerance) to conventional treatments ongoing for at least 12 months prior to inclusion. Conventional treatments must include all of the following: active physiotherapy, pharmacological treatment of pain and intra-articular infiltration.
  • Only for patients with Osteoarthritis (OA): Radiologic confirmation of knee osteoarthritis of grade 2 (mild), 3 (moderate) or 4 (severe) noted within 12 months prior to the screening for the index knee according the Kellgren Lawrence criteria diagnosed by an independent radiologist with experience in musculoskeletal imaging on radiography (Rx) or magnetic resonance imaging (MRI). If imaging will need to be performed at screening it is recommended to perform an MRI instead of Rx. Imaging with MRI will enable the independent radiologist to perform a better estimation of the grade of OA.
  • Only for patients with Persistent Post-Surgical Pain (PPSP) after Total Knee Arthroplasty (TKA): Patients with PPSP* after TKA need to have had a negative orthopaedic work-up

Exclusion criteria

Exclusion Criteria:

  • Local or systemic infection (bacteraemia).
  • Evidence of inflammatory arthritis or an inflammatory systemic disease responsible for knee pain.
  • Intra-articular injections (, hyaluronic acid, enriched plasma, ...) in the index knee during the 3 months prior to procedure.
  • Pregnant, nursing or planning to become pregnant before the study intervention. Participants who become pregnant after the study intervention during the follow-up period will not be excluded.
  • Chronic widespread pain.
  • Patients with unstable psychosocial disorder.
  • Allergies to products used during the procedure (lidocaine, propofol, chlorhexidine).
  • Uncontrolled coagulopathy defined as supratherapeutic dose of anticoagulation medication.
  • Uncontrolled immune suppression.
  • Participating in another clinical trial/investigation within 30 days prior to signing .
  • Patient is currently implanted with a neurostimulator.
  • Current radicular pain in index leg.
  • Previous conventional or cooled radiofrequency of the index knee.
  • Patients with bilateral knee pain defined as chronic knee pain (> 12 months) in both knees that is moderate to severe (defined as a numeric rating scale (NRS) > 4 on most or all days either constantly or with motion) and that is unresponsive (meaning insufficient pain reduction or intolerance) to conventional treatments ongoing for at least 12 months prior to inclusion. Conventional treatments must include all of the following: active physiotherapy, pharmacological treatment of pain and intra-articular corticosteroid infiltration.
  • Patients who have a planned TKA in the near future defined as patients who already have agreed on a date for the TKA procedure.
  • Patients who are unwilling or mentally incapable to complete the study questionnaires.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Active comparator
    Conventional Radiofrequency of the genicular nerves

    In the conventional radiofrequency group a intervention of 80°C at the tip is applied during 90 seconds at each nerve (superolateral, superomedial and inferomedial genicular nerves). The probe stays in place for 150 seconds at each nerve so that the time needed for each procedure is similar.

    Procedure: Conventional Radiofrequency ablation of the genicular nerves

  • Active comparator
    Cooled Radiofrequency of the genicular nerves

    In the cooled radiofrequency group a intervention of 60°C measured at the tip and on average 80°C in the targeted tissue is applied for 150 seconds using the Cooled RF system at each nerve (superolateral, superomedial and inferomedial genicular nerves).

    Procedure: Cooled Radiofrequency ablation of the genicular nerves

  • Sham comparator
    Sham procedure

    In the sham group a 18 gauge introducer and probe will be placed but no RF intervention will be applied. The generator will be turned on without connection to the probe for 150 seconds and the sound of the generator will be mimicked with a recording. The position of the needle will not be checked by fluoroscopy; however, the intervention team will position the fluoroscopy arm and mention the acquisition of the fluoroscopic image to the patient. This way no unnecessary radiation is used.

    Procedure: Sham procedure

Interventions

  • ProcedureConventional Radiofrequency ablation of the genicular nerves

    Conventional Radiofrequency treatment of the genicular nerves of the knee blocks the transmission of painful stimuli from the sensory genicular nerves of the knee to the central nervous system by means of a thermal lesion created using RF current.

    Also known as: Conventional Radiofrequency ablation

  • ProcedureCooled Radiofrequency ablation of the genicular nerves

    Cooled RF treatment causes a larger lesion size compared to conventional RF by means of internal cooling of the probe.

    Also known as: Cooled Radiofrequency ablation

  • ProcedureSham procedure

    Sham procedure with placing of needles subcutaneously.

06

What researchers measure

Primary outcomes

  1. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at 6 months post-intervention

    The primary endpoint is the WOMAC score (range 0-96) at 6 months post-intervention. The WOMAC score is derived from a self-administered osteoarthritis-specific validated questionnaire on pain, stiffness, and physical functioning of the knee joint.The lower the score, the lower the osteoarthritis-specific symptoms are.

    Time frame: 6 months post-intervention.

Secondary outcomes

  1. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score.

    The WOMAC score (range 0-96) is derived from a self-administered osteoarthritis-specific validated questionnaire on pain, stiffness, and physical functioning of the knee joint.The lower the score, the lower the osteoarthritis-specific symptoms are.

    Time frame: 1-, 3-, 6-, 12- and 24-months post-intervention.

  2. Pain Intentisty

    Pain intensity expressed by the Numerical Rating Scale (NRS) (range 0-10). The NRS score at each visit will be calculated as the mean score of the 4 days prior to each visit.The lower the score, the least pain the patient experiences.

    Time frame: 1-, 3-, 6-, 12- and 24-months post-intervention.

  3. The proportion of patients with a pain reduction of at least 50% compared to baseline expressed by the numerical rating scale (NRS)

    The proportion of patients with a pain reduction of at least 50% compared to baseline expressed by the numerical rating scale (NRS) (0-10). The NRS score at each visit will be calculated as the mean score of the 4 days prior to each visit.The lower the score, the least pain the patient experiences.

    Time frame: 1-, 3-, 6-, 12- and 24-months post-intervention.

  4. Health-related quality of life

    Health-related quality of life assessed by the EuroQoL-5D-5L (EQ-5D-5L). The questionnaire consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and a visual assessment scale. Responses to the 5 items (one for each dimension) result in a patient's health state that can be transformed into a utility score ranging between 0 (death) and 1 (full health), representing the quality of life of the health state. For the visual assessment scale section, the patient indicates their impression of health on the visual scale. The scale has the following distribution: 0 indicating "worse possible health" and 100 indicating "best possible health".

    Time frame: 1-, 3-, 6-, 9-, 12- and 24-months post-intervention.

  5. Goniometry

    Goniometry (maximal knee flexion and extension expressed in degrees) is assessed using the CJOrtho app. The degrees range from 0 to 180 degrees.

    Time frame: 1-, 3-, 6-, 12- and 24-months post-intervention.

  6. 'Timed up and Go' test

    The 'Timed up and Go' test assesses the physical functioning of the patient.

    Time frame: 1-, 3-, 6-, 12- and 24-months post-intervention.

  7. The 6-minute walk test

    The 6-minute walk test assesses the physical functioning of the patient. The distance in meters covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.

    Time frame: 1-, 3-, 6-, 12- and 24-months post-intervention.

  8. The Hospital Anxiety and Depression Scale (HADS)

    The Hospital Anxiety and Depression Scale (HADS) assesses and detect anxiety and depression in patients with physical health problems. The questionnaire consists of 14 items: 7 items to measure anxiety and 7 items to measure depression.

    Time frame: 1-, 3-, 6-, 12- and 24-months post- intervention.

  9. The Pain Catastrophizing Scale (PCS)

    The Pain Catastrophizing Scale (PCS) assesses the mental health of the patient.The 13 item questionnaire consists of 3 subscales (magnification, rumination and helplessness) and asks patients to reflect on past painful experiences and to indicate the degree on which they experiences each of 13 thoughts of feelings on a 5- point scale (0 not at all and 4 all the time).

    Time frame: 1-, 3-, 6-, 12- and 24-months post- intervention.

  10. Patient Global Impression of Change (PGIC)

    Patients' Patient's Global Impression of Change (PGIC) scale is a self-reported measure that reflects the patient's belief about the treatment efficacy. The patient is asked to rate the efficacy of the treatment on a scale of 1 (much better) to 7 (much worse).

    Time frame: 1-, 3-, 6-, 12- and 24-months post- intervention.

  11. Patient's satisfaction

    Patient's satisfaction assessed by 7-point Likert scale with 0 representing total dissatisfaction and 10 representing maximal satisfaction.

    Time frame: 1-, 3-, 6-, 12- and 24-months post- intervention.

  12. Medication use

    Medication use measured by Medication Quantification Scale III (MQS III).It computes a single numeric value for a patient's pain medication profile. This number is used to track pain levels through a treatment course or research study.

    Time frame: 1-, 3-, 6-, 9-, 12- and 24-months post- intervention.

  13. Opioid dependence

    The patient is strong opioid dependent if the patient takes an opioid analgesic with the exception of analgesics with tramadol or codeine.

    Time frame: 1-, 3-, 6-, 9-, 12- and 24-months post- intervention.

  14. Incidence of related adverse events

    The incidence of related adverse events. Active capture during each study contact to assess specific symptoms and adverse events relevant to chronic knee pain or RF intervention.

    Time frame: Follow-up until 24-months post- intervention.

  15. Health care resource utilisation

    The health care resource use questions are created for the COGENIUS study to collect information regarding the visits to a medical specialist (doctor or nurse) or general practitioner as a result of knee pain.

    Time frame: Follow-up until 24-months post- intervention.

  16. Productivity loss due to sickness

    Productivity loss due to sickness assessed by the Work Productivity and Activity Impairment (WPAI). Productivity loss due to sickness refers to output loss resulting from work absence and/or reduced labour input due to sickness. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.

    Time frame: Follow-up until 24-months post- intervention.

Other outcomes

  1. Phenotype of patients suffering from Persistent Post-Surgical Pain (PPSP)

    Demographic data collected at baseline will be used to phenotype patients suffering from PPSP.

    Time frame: Baseline

  2. Time to additional interventions

    Time to additional interventions at each time point. Interventions will be divided in minimally invasive interventions (intraarticular (IA) steroid injections, IA hyaluronic acid, platelet rich plasma of infiltrations, repeat RF of the genicular nerves) and surgery (primary/revision total knee arthroplasty and other knee related surgery) during the follow-up.

    Time frame: Follow-up until 24-months post- intervention.

07

Study locations

10 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Researcher will need to contact ctu@zol.be in order to request the 'Data Sharing Application' form. Users will need to complete an application form, 'Request for Data Sharing'. The application will be reviewed by the Trial Steering Committee with regard to feasibility and confidentiality. When the application is approved by the Trial Steering Committee, the applicant will be requested to sign a 'Data Use Agreement'. This Data Use Agreement shall be countersigned by ZOL as Sponsor and the CI of the COGENIUS study.

Time frame: Considering that ongoing research contributing to the completion of datasets must not be compromised by premature or opportunistic sharing and analysis of data, ZOL will not release the data of its studies until the primary study results have been published, unless authorized for release has been granted.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Mar 2025, 31 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 31 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2022
First posted
Jun 7, 2022
StartActual
Jul 7, 2022
Primary completionEst.
Mar 1, 2025
CompletionEst.
Sep 1, 2026
Last update
May 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05407610
Lead sponsor
Ziekenhuis Oost-Limburg
Collaborators
Belgium Health Care Knowledge Centre, Klinische Epidemiologie en Medical Technology Assessment
Responsible party
Jan Van Zundert (Professor, Ziekenhuis Oost-Limburg) — Principal investigator
First posted
Jun 7, 2022
Start date
Jul 7, 2022
Primary completion
Mar 1, 2025 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
May 24, 2023

Study contacts

Jan Van Zundert
Contact
cogenius@zol.be
+32 (0)89 32.52.54
Charlotte Claes
Contact
cogenius@zol.be
+32 (0)89 21.20.85

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion